Results 101 to 110 of about 3,967 (153)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing [PDF]

, 2022
Coppi, Marco, Giani, Tommaso, Rossolini, Gian Maria   +2 more
core   +1 more source

Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance [PDF]

[Abstract] Klebsiella pneumoniae carbapenemase (KPC) variants selected during ceftazidime/avibactam treatment usually develop susceptibility to carbapenems and carbapenem/β-lactamase inhibitors, such as imipenem and imipenem/relebactam.
Aja-Macaya, Pablo, Alonso-García, Isaac, Arca-Suárez, Jorge, Beceiro, Alejandro, Blanco-Martín, Tania, Bou, Germán, Fernández-López, María del Carmen, Gato, Eva, González-Pinto, Lucía, Martínez-Martínez, Luis, Outeda-García, Michelle, Pedraza-Merino, Rosa, Rodríguez-Coello, Arianna, Rodríguez-Pallares, Salud, Sánchez-Peña, Lucía, Vázquez-Ucha, Juan Carlos   +15 more
core   +1 more source

Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection

Infection and Drug Resistance
Ignacy Tarski,1 Jakub Śmiechowicz,2 Wiesława Duszyńska2 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; 2Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw ...
Tarski I, Śmiechowicz J, Duszyńska W
doaj  

Characterization of Enterobacter cloacae and Citrobacter freundii Species Complex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam–Avibactam and Comparator Agents (2019–2023)

Antibiotics
Background: Citrobacter freundii (CFC) and Enterobacter cloacae (ECLC) species complexes represent important causes of hospital-associated infections, frequently are related to outbreaks, and have a great ability to develop antimicrobial resistance.
Helio S. Sader, Timothy B. Doyle, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +4 more
doaj   +1 more source

Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa [PDF]

[Abstract] Objectives: We aimed to compare the stability of the newly developed β-lactams (cefiderocol) and β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam/avibactam, cefepime/taniborbactam ...
Alonso-García, Isaac, Arca-Suárez, Jorge, Beceiro, Alejandro, Blanco-Martín, Tania, Bou, Germán, Camacho-Zamora, Pablo, Fraile-Ribot, Pablo Arturo, González-Pinto, Lucía, Guijarro-Sánchez, Paula, Juan, Carlos, Lasarte-Monterrubio, Cristina, Maceiras, Romina, Moya, Bartolomé, Oliver, Antonio, Outeda, Michelle, Vázquez-Ucha, Juan Carlos   +15 more
core   +1 more source

Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested Against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019–2023)

Antibiotics
Objective: To evaluate the antimicrobial susceptibility of Enterobacterales isolated from pediatric patients. Methods: A total of 5723 isolates were consecutively collected (1/patient) from pediatric patients (
Helio S. Sader, Marisa L. Winkler, Krisztina M. Papp-Wallace, Rodrigo E. Mendes, Mariana Castanheira   +4 more
doaj   +1 more source

Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen. [PDF]

Int J Antimicrob Agents, 2023
Singh S, Gumbo T, Alffenaar JW, Boorgula GD, Shankar P, Thomas TA, Dheda K, Malinga L, Raj P, Aryal S, Srivastava S.   +10 more
europepmc   +1 more source

Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/ Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate [PDF]

, 2022
Bianco, Gabriele, Boattini, Matteo, Costa, Cristina   +2 more
core   +1 more source

Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales. [PDF]

J Antimicrob Chemother, 2023
Nordmann P, Kerbol A, Bouvier M, Sadek M, Poirel L, Raro OHF.   +5 more
europepmc   +1 more source

Complete genome sequences of KPC-producing <i>Klebsiella pneumoniae</i> isolates pre- and post-development of meropenem/vaborbactam resistance. [PDF]

Microbiol Resour Announc
Ozer EA, Nozick SH, Singh N, Watkins JV, Hauser AR, Bulman ZP.   +5 more
europepmc   +1 more source